Bevirimat dimeglumine: Phase II data

A retrospective analysis of 2 Phase II trials evaluating bevirimat in 100 patients with HIV-1 infection showed that a companion diagnostic based on 5 key amino acids in HIV gag polyprotein correctly predicted 43 of 52 bevirimat responders and 41 of 48 non-responders. A responder was defined as achieving a >= 0.8 log 10 viral load decrease at day 15. The algorithm had predicted 54 responders and 46 non-responders. ...